Tag: Thrombosis risk

Elevated von Willebrand factor (VWF) levels are a known risk factor for thrombotic events, including ischemic stroke and venous thromboembolism. In contrast to treating von Willebrand disease (VWD), where VWF levels are low, the management of a high von Willebrand factor does not involve direct drug-induced reduction but rather addresses the underlying cause and associated thrombotic risk.

Tranexamic acid is an antifibrinolytic drug used to manage or prevent heavy bleeding in various medical scenarios. Given its effect on blood clotting, understanding **what medication not to take with tranexamic acid** is crucial for patient safety and avoiding dangerous, even life-threatening, side effects.

The Institute for Safe Medication Practices (ISMP) added tranexamic acid (TXA) injection to its List of High-Alert Medications in 2024 [1.2.3, 1.5.2]. This classification begs the question: why is tranexamic acid a high alert medication? The answer lies in the severe harm it can cause if administered incorrectly [1.2.3].

Medication errors involving tranexamic acid being administered incorrectly via the spinal column have a mortality rate of approximately 50% [1.2.5]. These devastating outcomes are at the core of a significant portion of legal actions and medical malpractice claims related to the drug. So, what is the lawsuit about tranexamic acid? It primarily concerns catastrophic administration errors and, to a lesser extent, risks of side effects.